Stop Patent Hops: Detecting “Evergreening” Patterns Through Sequential FDA Orange Book Listings
The pharmaceutical industry operates on a model where the expiration of a primary patent is no longer the end of […]
How to stop a 90% revenue crash: Mapping patent thickets to survive the new exclusivity slope
The Cliff Is Real, and the Numbers Are Getting Worse The pharmaceutical revenue cliff is not a metaphor. It is
The Smarter Drug Approval Path Most Companies Still Ignore: A Comparative Analysis of 505(b)(2) and 505(b)(1) Regulatory Pathways
The pharmaceutical industry spent roughly $2.3 billion and 12 years, on average, bringing a single new molecular entity to market
Patent Gaps Pay: The Regional Launch Windows Hidden Inside Abandoned Drug Patents
Every year, pharmaceutical companies abandon thousands of patents. They miss maintenance fee deadlines. They fail to validate patents in markets
Patent Gaps Pay: The Regional Launch Windows Hidden Inside Abandoned Drug Patents Read Post »
De-Risk Your Pipeline: The Definitive Guide to Freedom-to-Operate Analysis in Biopharma
What FTO Actually Means (And What It Doesn’t) The Legal Definition and Its Limits Freedom-to-operate analysis is one of the
De-Risk Your Pipeline: The Definitive Guide to Freedom-to-Operate Analysis in Biopharma Read Post »
How Drug Companies Turn 20-Year Patents Into 40-Year Monopolies
Humira, AbbVie’s blockbuster arthritis drug, generated more than $200 billion in cumulative revenue before biosimilar competitors could reach American patients
How Drug Companies Turn 20-Year Patents Into 40-Year Monopolies Read Post »
Count What Matters: Advanced Metrics to Value a Pharma Patent Portfolio Before the Generic Cliff
The Problem With Citation Counts A patent that has been cited 400 times sounds impressive. An IP manager can drop
After the Patent: Big Pharma’s Branded Generic Playbook
The Problem Nobody Admits Out Loud Every large pharmaceutical company has the same conversation at some point. A blockbuster drug
After the Patent: Big Pharma’s Branded Generic Playbook Read Post »
30 Months vs. 9 Months: How the US and China Patent Linkage Gap Reshapes Global Drug Competition
A comparative analysis of the statutory stay periods that define when generic and biosimilar manufacturers can enter the world’s two
